SLC5A2 and type 2 diabetes mellitus: Regarding the inflammatory cytokine, IL-6, a recent meta-analysis involving more than 5000 adult individuals with T2DM, the use of SGLT2 inhibitor reduced IL-6 by a mean of 1.04 and 1.3 compared to other antidiabetic medications [21].